Last month, an experimental pancreatic cancer drug from Infinity Pharmaceuticals ( INFI) failed a mid-stage study because patients were not living longer. Clovis Oncology ( CLVS) and Celgene ( CELG) are each, separately, conducting studies of pancreatic cancer drugs with results expected later this year. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.